Wellness

[cherry]

testing

[cherry]

sorry for some reason I can't post an article I want to share about a new type 2 from Isreal..It sounds very promisng and has won awards

snip

he FDA has already approved clinical trials after the company completes a series of pre-clinical toxicology studies on the drug.


“We are working on accommodating those requests and making the final formulation of the drug as a pill. We plan to perform clinical studies here in Israel. Then we will submit another IND (Investigational New Drug) application to go to phase 2b, by the end of 2020. We are currently raising funds to do all of that,” Chevion told ISRAEL21c.

The company is currently raising $5 million to fund this year’s tests on the drug.

“The estimated cost of treating diabetes per year is over $850 billion. More than 150 companies are developing diagnostics or applications for diabetes, but there are no drugs to treat the actual problem of insulin resistance without side effects. This is what we are doing,” he said.

Concenter BioPharma has already received recognition.

The small company won first place at the 17th Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Diseases in December.

[cherry]

this website is a mess

[cherry]

Concenter BioPharma created a new non-steroidal anti-inflammatory drug called Zygosid-50 that targets the disease at its source by restoring the body’s sensitivity to insulin.

Insulin is the hormone that keeps your blood sugar from getting too high after you eat. Type 2 diabetes occurs when the body is no longer sensitive to insulin or the pancreas does not make enough.

Related

'A Weapon You Can't See or Hear': Israeli Breakthrough Can Thwart Missile Barrages

Concenter Biopharma cofounder and CSO Prof. Mottie (Mordechai) Chevion developed the drug at Hebrew University-Hadassah Medical Center in Jerusalem.

“Zygosids work by robustly reducing insulin resistance and normalizing all diabetes-associated parameters to the normal range,” the professor told ISRAEL21c. “On the molecular level, Zygosid-50 is a potent anti-inflammatory drug that forces an intra-cellular exchange – removal of ‘bad’ free iron with zinc, depositing the zinc ion within the cells.”

When researchers tested Zygosid-50 on animals, it was able to restore insulin sensitivity by more than 90%, lowered glucose, and suppressed high inflammation levels within the body.

Chevion explained that the drug had no bad side effects on animals. Now, the company is working to get the new drug approved by the United States Food and Drug Administration.

The FDA has already approved clinical trials after the company completes a series of pre-clinical toxicology studies on the drug.


“We are working on accommodating those requests and making the final formulation of the drug as a pill. We plan to perform clinical studies here in Israel. Then we will submit another IND (Investigational New Drug) application to go to phase 2b, by the end of 2020. We are currently raising funds to do all of that,” Chevion told ISRAEL21c.

The company is currently raising $5 million to fund this year’s tests on the drug.

“The estimated cost of treating diabetes per year is over $850 billion. More than 150 companies are developing diagnostics or applications for diabetes, but there are no drugs to treat the actual problem of insulin resistance without side effects. This is what we are doing,” he said.

Concenter BioPharma has already received recognition.

The small company won first place at the 17th Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Diseases in December.

 

 

[cherry]

A new cell treatment to enhance islet transplantation could help maintain healthy blood sugar levels in Type 1 diabetes without the need for multiple transplants of insulin producing cells or regular insulin injections, research suggests.

In Type 1 diabetes the insulin-producing cells of the pancreas are destroyed. Insulin injections maintain health but blood glucose levels can be difficult to control. Currently in the UK it is estimated that approximately 400,000 people in the UK have type 1 diabetes.

The current recommendation for people with type 1 diabetes who have lost awareness of low blood glucose levels is the transplantation of islets – the insulin producing part of the pancreas.

A study in mice found that transplanting a combination of islets with connective tissue cells found in umbilical cords – known as stromal cells - could potentially reduce the number of pancreases required for the procedure. 

Mice that received the islet-stromal cell combination were found to have better control of blood glucose and less evidence of rejection of islets after seven weeks, compared to those that received islets alone.

In humans, more than two donor pancreases, which are scarce, are often needed because islets can be rejected and are slow to form new blood supplies. 

Therefore, multiple islet transplantations and anti-rejection medication are required to control blood sugar levels in people with Type 1 diabetes. Scientists at the University of Edinburgh hope their findings could be a way of overcoming these issues. 

The researchers found that islets combined with stromal cells successfully returned normal blood glucose levels just three days after transplantation. 

Other studies have used cells sourced from bone marrow and fat. This is the first to use stem cells from umbilical cords and has produced superior results.

The research is published in the journal Science Translational Medicine and funded by Chief Scientist Office in Scotland and Diabetes UK.

Shareen Forbes, Professor of Diabetic Medicine at the University of Edinburgh and Lead Physician for the Islet Transplant Program in Scotland, said: “Should this research prove successful in humans, we could reduce the number of islets needed to control blood sugar levels using this co-transplantation approach. This would mean more people with Type 1 diabetes could be treated using islet transplantation while significantly reducing the waiting time on the transplant list.”

John Campbell, Professor and Associate Director Tissues, Cells & Advanced Therapeutics at the Scottish National Blood Transfusion Service has said that further work is needed to establish the long-term safety of using this type of stromal cell in this setting before proceeding to clinical trials in humans.

Dr. Elizabeth Robertson, Director of Research at Diabetes UK, said: “Islet transplants have been life changing for some people with Type 1 diabetes, treating dangerous hypo unawareness. But there currently aren’t enough donated pancreases to go around, and the procedure itself isn’t yet as effective as it could be. 

“This new research from the University of Edinburgh is a promising step forward, and one we hope will lead to islet transplants becoming both more effective and more widely available in the future.”

[cherry]

Fruit and Diabetes: What You Need To Know

---

One of our PEP Squad (Parents Empowering Parents) moms with a newly diagnosed child wanted to know the do’s and don’ts of “fruit and diabetes.” So, we asked for more info from the expert nutritionists at the DRI, and we think you’ll like the advice they offered up. (HINT: You can still enjoy fruit’s sweet, juicy goodness!) Here’s what you need to know:

Fruits are delicious and very healthy! Be smart with your choices. And remember one serving of fruit contains 15 grams of carbohydrates, so keep an eye on portions!

*Ranks how certain foods affect blood sugars.

[cherry]

Patient Groups Urge Supreme Court to Swiftly Take Up Health Care Case

January 16, 2020

Arlington, Virginia

Groups Argue Patients Need A Quick Resolution to Ensure Access to Care

Patient and health advocacy groups representing millions of Americans with pre-existing conditions filed an amicus curiae or friend of the court brief urging the U.S. Supreme Court to immediately take up the case of Texas v. United States. The case is the latest court challenge to the health care law known as the Affordable Care Act. The groups, which include the American Cancer Society Cancer Action Network, American Diabetes Association, American Heart Association, American Lung Association, and the National Multiple Sclerosis Society along with more than a dozen others, cite the detrimental impacts and uncertainty patients would face with a prolonged delay should the case be left at the lower court level.

Following is the groups’ joint statement:

“Millions of Americans who rely on the health care law and its critical patient protections cannot wait for the lower court to determine which, if any, parts of the Affordable Care Act should remain in place. This ongoing uncertainty threatens their ability to obtain and afford care necessary for their health and well-being. It also threatens to erode the insurance markets which need clear, stable rules on which to price and offer coverage.

“Should the Supreme Court decline to take action, millions of people with pre-existing health conditions will have to worry whether they’ll again be denied coverage if the law is overturned. Millions of Americans who rely on federal tax credits to help pay for their health insurance will be unsure if they’ll have affordable coverage in the years to come. And health plans could raise their premiums in response to the uncertainty in the market.

“The health care law has expanded access to comprehensive health coverage to millions of previously uninsured Americans. The connection between health coverage and health outcomes is clear. Without affordable, comprehensive health insurance patients, survivors, and their families risk later stage diagnoses—if they can get care at all—and an increased risk of serious financial strain. Americans need to know what coverage options will be available as soon as possible, which underscores the need for an expedited final ruling in this case.

“On behalf of all the patients we represent, we urge the Supreme Court to swiftly resolve this case and provide the clarity and certainty people and the health care system need.”

View the full brief: https://bit.ly/38dIb8j

[cherry]

Undo

People With Type 2 Diabetes Should Get Calcium Levels Tested for Hypoparathyroidism, Case Report Suggests

hypoparathyroidismnews.com/2020/01/22/type-2-diabetes-patients-should-have-calcium-test-for-hypopara...

Catarina Silva, MScJanuary 22, 2020

People with type 2 diabetes mellitus and muscle pain should have the calcium levels in their blood measured to check for hypoparathyroidism, a case report suggests.

The study, “Type 2 diabetes mellitus complicated with idiopathic hypoparathyroidism where poor glycaemic control...,” was published in the journal BMJ Case Reports.

People with idiopathic (no known cause) hypoparathyroidism have abnormally low secretion of parathyroid hormone (PTH), which regulates calcium levels in the blood. Calcium is crucial for several functions, including bone development, blood clotting, and muscle contraction.

Low PTH levels lead to low calcium concentrations and may manifest as muscle pain (myalgia), fatigue, or weakness. Because these symptoms are common in other disorders, physicians may overlook idiopathic hypothyroidism as a possible diagnosis.

Researchers at Yokohama Rosai Hospital in Japan reported on a 36-year-old obese man who was admitted to the hospital with persistently high blood sugar and low calcium levels, or hypocalcemia.

Two months earlier, his calcium level had been 6.1 mg/dL (normal range is 8.5 to 10.5 mg/dL), and his glycated hemoglobin (HbA1c) — an indicator of diabetes — was 11.1% (less than 6% is normal). He was taking four different oral treatments per day to lower blood sugar levels: metformin, vildagliptin, mitiglinide, and voglibose.

The man — whose mother had type 2 diabetes and was receiving treatment with insulin — had a history of asthma, and was diagnosed with type 2 diabetes when he was 30. Despite effective reduction of blood sugar levels over six months, he began to complain of muscle pain in his legs, which prevented him from adequate physical exercise.

The man attributed the onset of myalgia to the prescribed treatment plan, and started to cut back on exercise and medication. His blood calcium levels were not measured at the time.

Subsequent tests revealed high blood levels of phosphate, creatine kinase — an indicator of muscle damage — and triglycerides (fat), as well as low magnesium levels and insulin resistance. He also had low levels of intact PTH and 1,25-(OH)2 vitamin D3, an active form of vitamin D.

Neurological examination showed decreased vibratory sensation and tendon reflexes (which determine muscle contraction upon tapping) in his lower limbs. Brain imaging revealed no abnormalities.

Because there was no previous medical or family history or physical or laboratory findings that would indicate another disease, the patient was diagnosed with idiopathic hypoparathyroidism. He was treated with metformin and liraglutide, and given a daily diet plan of 1,900 calories. Correction of serum calcium levels with calcitriol (an active vitamin D analog) was associated with complete relief of muscle pain.

The man was able to exercise regularly and comply with the prescribed medications and diet. Three months after discharge, he had lost weight, his serum calcium levels were stable, and his HbA1c levels were close to normal (7.1%).

While idiopathic hypoparathyroidism is a rare disease, it can make it difficult to control blood sugar levels by inducing insulin resistance, which is linked to reduced mobility, the scientists said.

“Based on our findings, we recommend checking serum calcium levels in patients with T2DM [type 2 diabetes mellitus] to identify underlying hypoparathyroidism, particularly in those who experience symptoms of myalgia,” they wrote.

• Author Details

Catarina Silva, MSc

With over three years of experience in the medical communications business, Catarina holds a BSc. in Biomedical Sciences and a MSc. in Neurosciences. Apart from writing, she has been involved in patient-oriented translational and clinical research.

×

Catarina Silva, MSc

With over three years of experience in the medical communications business, Catarina holds a BSc. in Biomedical Sciences and a MSc. in Neurosciences. Apart from writing, she has been involved in patient-oriented translational and clinical research.

Latest Posts

• 
• 

[cherry]

Here is a report from consumer reports, rating the best drug for type 2 diabetes

https://www.consumerreports.org/video/view/healthy-living/drugs-medication/77044365001/type-2-diabet...

[cherry]

People with type 2 diabetes should 'save carbs for last', study claims

Monday 2 October 2017

"Diabetics should save bread for last at mealtime to keep their blood sugar under control," the Mail Online reports. A small study found that people with type 2 diabetes who saved their carbohydrates until the end of their meal were less likely to experience a sudden rise in their blood sugar (glucose) levels. The medical term for this spike in blood sugar levels is postprandial hyperglycaemia.

Postprandial hyperglycaemia is best avoided as not only can it make the day-to-day symptoms of diabetes worse, it has also been linked to an increased risk of developing cardiovascular disease.

It has been suggested that leaving carbohydrates until the end of a meal could slow the emptying of the stomach and give it a chance to digest the protein and vegetables first, which could help prevent a blood glucose spike. The researchers wanted to see whether this was true.

This study included just 16 people who ate the foods of their meal in different orders to test which order was most effective at lowering blood sugar and related hormones. They either ate carbohydrates first, carbohydrates last, or all nutrients together at the same time.

The researchers generally found that consuming carbohydrates last was better at lowering blood sugar levels and insulin secretion when compared to the other ways of eating carbohydrates.

While the results are interesting, the study was far too small to form the basis of any firm medical guidance. For now, it's best to follow current advice, which is to consume a healthy diet and keep active to help you manage your blood sugar level. This will also help you control your weight and generally feel better.

Where did the story come from?

The study was carried out by US researchers from Weill Cornell Medical College, Columbia University and Boston Children's Hospital. It was funded by the Louis and Rachel Rudin Foundation Grant, and Diane and Darryl Mallah from The Diane and Darryl Mallah Family Foundation.

The study was published in the peer-reviewed BMJ Open Diabetes Research & Care. It is available on an open-access basis and can be read for free online (PDF, 404kb).

The Mail Online's coverage generalised the results to all diabetics – but the study only looked at those with type 2 diabetes. People with type 1 diabetes typically require insulin injections to keep their blood sugar levels under control.

It also presented the findings as if they were a solid recommendation, but this is not the case, especially given this was an early-stage study using a very small number of people.

What kind of research was this?

This was a randomised crossover trial that aimed to determine the best time during a meal to eat carbohydrates to lower blood glucose levels in individuals with type 2 diabetes. The researchers also wanted to explore whether changing the order in which foods were eaten during a meal had any effect on the secretion of insulin and other glucose-regulating hormones.

Previous research has suggested that saving carbohydrates until the end of the meal lowers blood glucose levels. This follows on from the notion that eating proteins at the start of a meal stimulates insulin secretion (which helps control glucose levels). However, data on this hypothesis is limited and the researchers of this study wanted to investigate this idea further.

Crossover trials such as this are often used when the sample size is very small. Each person acts as their own control, which effectively increases sample size. The study would ideally need to be conducted using a much larger sample with people randomised to consume nutrients in different orders over a longer period to compare effects.

What did the research involve?

The researchers recruited 16 people with type 2 diabetes, between the ages of 35 and 65. All the participants had a body mass index (BMI) of between 25 and 40kg/m2 (covering the range from overweight to severely obese) and had been diagnosed with diabetes within the last 10 years.

All 16 people consumed the same meal on three separate days spaced out one week apart, with each meal following a 12-hour overnight fast. The meals varied in terms of the order in which the nutrients were eaten. Participants were assigned the following meal types in random order:

• carbohydrates first, followed by protein and vegetables 10 minutes later
• protein and vegetables, followed by carbohydrates 10 minutes later
• all nutrients eaten together

Blood samples were taken before consumption, and then at 30-minute intervals up to 180 minutes. The following were measured:

• glucose levels
• insulin levels (a hormone released in response to high glucose levels)
• glucagon-like peptide-1 (GLP-1, a hormone secreted in the gut in response to food to signal the release of insulin)
• glucagon levels (a hormone released in response to low glucose levels)

All participants were instructed to maintain their usual level of diet and physical activity during the full study period.

What were the basic results?

The following was observed:

• When carbohydrate was consumed last, lower levels of insulin were secreted (24.8% lower than the meal with carbohydrates first), which would suggest a smaller spike in glucose. There was no significant difference between eating carbohydrates last and having all nutrients together.
• Consistent with this, glucose levels were 53.8% and 40.4% lower in the meal with carbohydrates last compared to having carbohydrates first and all nutrients together, respectively.
• The GLP-1 levels were higher in people who ate carbohydrates last.
• Glucagon levels were not significantly different between the three meal conditions.

How did the researchers interpret the results?

The researchers concluded: "In this study, we demonstrated that the temporal sequence of carbohydrate ingestion during a meal has significant impact on postprandial glucose regulation. These findings confirm and extend results from our previous pilot study; the inclusion of a third nutrient order condition, a sandwich, had intermediate effects on glucose excursions compared with carbohydrates last versus carbohydrates first."

Conclusion

This crossover trial investigated the optimal time to eat carbohydrates during a meal to lower blood glucose levels in individuals with type 2 diabetes. It generally found that consuming carbohydrates last was better at lowering glucose levels and reducing insulin secretion when compared to having carbohydrates first or all nutrients together.

The researchers say that suggesting people with type 2 diabetes follow this advice may be an effective behavioural strategy to improve glucose levels after meals.

Although the findings are interesting, there are a few points to note:

• Most importantly, this study was very small. A study using a much larger sample could give completely different results. Ideally the findings would need to be verified in a well-designed trial that randomised a much larger number of people with type 2 diabetes to consume their nutrients in a specific order, and then followed their response to this pattern over a longer period of time.
• There may be other factors affecting individual responses to the order of carbohydrate consumption – for example, the level of physical activity was not standardised across all participants. Again this is another factor that would need to be controlled in a larger trial.
• We are all different – and saving carbohydrates until the end of a meal may only be effective for some people with type 2 diabetes, and not others.
• The findings cannot be applied to people with type 1 diabetes.

These findings may pave the way for further research through larger trials, which in time may result in a change in the current recommendations for meal consumption for people with type 2 diabetes.

However, they have no current implications. For now, a healthy diet and keeping active will help you manage your blood sugar level. This will also help you control your weight and generally feel better.

Analysis by Bazian
Edited by NHS Website